ASTRAZENECA PHARMACEUTICALS LP for ASTRAZENECA PHARMACEUTICALS LP

Consumer Issues/Safety/Products CSP

Prescription Drug Importation FDA Globalization Act of 2009-US House FDA preemption

Contacted: U.S. Agency for International Development (USAID); U.S. Trade Representative (USTR); SENATE; Congressional Budget Office (CBO); Commerce, Dept of (DOC); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS)

Pharmacy PHA

Direct-to-Consumer Drug Advertising Discussions regarding Funding of FDA

Contacted: U.S. Agency for International Development (USAID); Congressional Budget Office (CBO); Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); Commerce, Dept of (DOC); SENATE; HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR)

Trade (domestic/foreign) TRD

International trade issues, including free-trade agreements and negotiations Import Safety

Contacted: U.S. Trade Representative (USTR); Commerce, Dept of (DOC); Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); Congressional Budget Office (CBO); U.S. Agency for International Development (USAID); SENATE; HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS)

Taxation/Internal Revenue Code TAX

Tax issues, including economic stimulus legislation, repatriaion and deferral, and bilateral tax issues

Contacted: Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; U.S. Agency for International Development (USAID); SENATE; Commerce, Dept of (DOC); U.S. Trade Representative (USTR); Congressional Budget Office (CBO)

Copyright/Patent/Trademark CPT

Patent Reform and intellectual property issues Section 182 ("Special 301") briefings on global intellectual property protections Discussions regarding patent settlements (reverse payments) legislation Discussions regarding follow on biologics

Contacted: U.S. Agency for International Development (USAID); Congressional Budget Office (CBO); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); SENATE; Health & Human Services, Dept of (HHS); U.S. Trade Representative (USTR); Commerce, Dept of (DOC); Centers For Medicare and Medicaid Services (CMS)

Health Issues HCR

Health Care Reform S. 301 Grassley/Kohl Physician Payments Sunshine Act of 2009 Mental Health Parity 340B Program - regarding legislation that would require extension of 340B pricing to pharmacies who also serve patients who do not qualify for 340B services VA/DoD Tricare - regarding TRICARE retail rebate legislation/rulemaking Discussions regarding global access to medicines Legislation or possible legislation regarind stem cell research Discussions regarding possible opportunities to work with CMS on education and outreach efforts

Contacted: U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES; Commerce, Dept of (DOC); Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); Congressional Budget Office (CBO); U.S. Agency for International Development (USAID); SENATE; Centers For Medicare and Medicaid Services (CMS)

Bills named: S. 301 (111th)

Medicare/Medicaid MMM

Medicaid - regarding possible increase in Medicaid base rebate; other issues regarding possible changes to Medicaid rebate program Comparative Effectiveness - regarding use of Comparative effectiveness in health care coverage and/or reimbursement Medicare - regarding "non-interfence" clause, protected classed of drugs, and Medicare Advantage

Contacted: Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; U.S. Agency for International Development (USAID); Health & Human Services, Dept of (HHS); Congressional Budget Office (CBO); SENATE; U.S. Trade Representative (USTR); Commerce, Dept of (DOC)